RedHill Biopharma shares jump on progress toward treating GLP-1 side effects
I'm PortAI, I can summarize articles.
RedHill Biopharma Ltd. (NASDAQ:RDHL) shares surged 16.5% in premarket trading following the company's announcement of progress in developing RHB-102 (Bekinda), a treatment targeting gastrointestinal side effects associated with GLP-1/GIP weight-loss and diabetes medications. The biopharmaceutical firm is advancing RHB-102, a once-daily oral ondansetron formulation, through the U.S. regulatory process.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments